Clinical trials for Differentiated thyroid carcinoma
9 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGN/ANCT07068542Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid CancerZhejiang Provincial People's Hospital · PI: Minghua Ge
- RECRUITINGPhase 3NCT06860971A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid CarcinomaChia Tai Tianqing Pharmaceutical Group Co., Ltd.
- RECRUITINGPhase 2NCT06440850Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E MutationCity of Hope Medical Center · PI: Sasan Fazeli
- RECRUITINGPhase 2NCT06359847Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid CancerBeijing Scitech-Mq Pharmaceuticals Limited · PI: Yansong Lin, Ph D
- RECRUITINGNCT05994365Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid CarcinomaChia Tai Tianqing Pharmaceutical Group Co., Ltd.
- ACTIVE NOT RECRUITINGN/ANCT06422702The Effect of a Psychosomatic Symptom Intervention Program on the Primary Treatment of Differentiated Thyroid CancerHarbin Medical University
- ACTIVE NOT RECRUITINGNCT04970134Spanish Study for Molecular Characterization of Thyroid CarcinomaGrupo Español de Tratamiento de Tumores de Cabeza y Cuello · PI: Neus Basté Rotllan, M.D. Ph.D.
- ACTIVE NOT RECRUITINGPhase 2NCT05007093Study on the Treatment of Differentiated Thyroid Carcinoma with AnlotinibYansong Lin
- ACTIVE NOT RECRUITINGNCT02185560Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With SorafenibBayer · PI: Bayer Study Director